Holen Sie sich die Stockscreener-App
51.34
0.12%
0.06
Handel nachbörslich:
51.70
0.36
+0.70%
Schlusskurs vom Vortag:
$51.28
Offen:
$50.442
24-Stunden-Volumen:
4.80M
Relative Volume:
0.42
Marktkapitalisierung:
$20.36B
Einnahmen:
$1.94B
Nettoeinkommen (Verlust:
$-2.82B
KGV:
-7.07
EPS:
-7.2617
Netto-Cashflow:
$-2.08B
1W Leistung:
-4.80%
1M Leistung:
+1.62%
6M Leistung:
+98.38%
1J Leistung:
+50.25%
1-Tages-Spanne:
$50.34
$52.68
1-Wochen-Bereich:
$50.19
$53.36
52-Wochen-Spanne:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
51.34 | 20.34B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna stands as the best performing large-cap healthcare stock YTD (XLV:NYSEARCA) - Seeking Alpha
Moderna, Heidrick & Struggles Execs Talk AI Execution - WSJ
Moderna Inc. stock faces analyst pressure amid patent settlement with Arbutus Biopharma - AD HOC NEWS
Moderna's Spikevax Vaccine: Current Status and Future Prospects in mRNA Technology Evolution - AD HOC NEWS
Lobbying Update: $100,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Moderna's Spikevax Vaccine: Latest Developments and Future Prospects as of March 2026 - AD HOC NEWS
ABUS: $2.25B Moderna settlement and improved net loss highlight strong 2025 performance - TradingView
ABUS: Secured $950M settlement with Moderna, reduced net loss, and streamlined operations in 2025 - TradingView
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Hudson Bay Capital Management LP Lowers Stake in Moderna, Inc. $MRNA - MarketBeat
VIX Spike: Is Moderna Inc a momentum stock2026 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Rate Hike: Should you avoid Moderna Inc stock right nowAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Trade Recap: Is now the right time to enter Moderna Inc2026 Dividend Review & Daily Stock Momentum Reports - baoquankhu1.vn
Moderna Inc. stock faces headwinds amid pipeline delays and FDA vaccine policy shifts - AD HOC NEWS
Aug Macro: Can Moderna Inc continue delivering strong returnsWeekly Stock Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat
Moderna's Spikevax Vaccine Faces Renewed Scrutiny Amid Biotech Sector Momentum and Safety Data Revel - AD HOC NEWS
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
COMMENTARY: An erratic FDA is a threat to innovation - Jefferson City News Tribune
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Therapeutics Sector Q4 Results: Revenue Beats Amid Market Stability - IndexBox
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest - Yahoo Finance UK
What triggered Moderna shares' latest price pullback - Traders Union
Why Moderna (MRNA) Is Down 6.4% After Cancer Vaccine Data And Flu Shot’s Expedited FDA Review - Yahoo Finance UK
Pfizer vs Moderna 2026: Pipeline Prospects After Vaccine Sales DropNews and Statistics - IndexBox
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Globe and Mail
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Motley Fool
MODERNA, INC. (MRNA) - MSN
Moderna shares see a dip: what is pressuring the stock - Traders Union
Opinion: An erratic FDA is a threat to innovation - Yakima Herald-Republic
Editorial: Erratic FDA is a threat to innovation - The Daily Reflector
Moderna shares see a jump — What is fueling the stock rise - Traders Union
Federal Judge Blocks RFK Jr. Vaccine Policy Shift: Spikevax's Path Forward Stabilized - AD HOC NEWS
Militia Capital Partners LP Sells 49,000 Shares of Moderna, Inc. $MRNA - MarketBeat
An erratic FDA is a threat to innovation - Hawaii Tribune-Herald
Times Opinion: An erratic FDA is a threat to innovation - Chattanooga Times Free Press
Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 millionSEC filing - marketscreener.com
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery - FinancialContent
Form DEFA14A Moderna, Inc. - StreetInsider
US Health Secretary Kennedy's vaccine actions and policy positions - marketscreener.com
Moderna, Inc. Trade Ideas — LS:A2N9D9 - TradingView
Moderna Clears Legal Hurdle and Advances Vaccine Pipeline - AD HOC NEWS
Moderna (MRNA) Is Down 5.7% After Costly LNP Settlement And Multi-Pathogen Trial UpdateHas The Bull Case Changed? - simplywall.st
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA - TradingView
Moderna (MRNA) Valuation Check As Multi Pathogen mRNA Study Completion And FDA Shifts Draw Fresh Focus - Yahoo Finance
Moderna Impfstoff Spikevax 2025-2026: What Changed This Year - AD HOC NEWS
Moderna Impfstoff (Spikevax) in 2026: Key Updates - AD HOC NEWS
Moderna (MRNA) Valuation Check After Sharp Multi‑Month Share Price Rebound - simplywall.st
Moderna Impfstoff (Spikevax): What Changed in 2026 - AD HOC NEWS
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):